Tags

Type your tag names separated by a space and hit enter

Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Urology. 2008 Nov; 72(5):1061-7; discussion 1067.U

Abstract

OBJECTIVES

To evaluate the efficacy of tolterodine extended release (ER), tamsulosin, and tolterodine ER plus tamsulosin in men with symptoms of overactive bladder and benign prostatic hyperplasia stratified by prostate-specific antigen (PSA) level.

METHODS

We performed a post hoc analysis of data from men >or=40 years old with frequency and urgency (with or without urge urinary incontinence), postvoid residual urine volume <200 mL, maximal urinary flow rate >5 mL/s, International Prostate Symptom Score (IPSS) of >or=12, and quality-of-life score of >or=3. They had been randomized to placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER plus tamsulosin for 12 weeks. The men were stratified by the median baseline PSA level (>or=1.3 vs <1.3 ng/mL). Assessments included changes in bladder diary variables and IPSSs. The men rated the urgency level of each micturition, and the frequency-urgency sum was defined as the total of these ratings.

RESULTS

The PSA level correlated significantly with prostate size. Men with a PSA level of >or=1.3 ng/mL receiving tolterodine ER plus tamsulosin showed significantly greater improvements in 24-hour frequency, daytime frequency, the frequency-urgency sum, total IPSS, and IPSS storage score compared with those receiving placebo. Tamsulosin significantly improved the IPSS voiding scores, but tolterodine ER was ineffective. In men with a PSA level <1.3 ng/mL, tolterodine ER alone and tolterodine ER plus tamsulosin significantly improved the 24-hour frequency, daytime frequency, frequency-urgency sum, and IPSS storage scores compared with those receiving placebo; tamsulosin alone was ineffective. No significant changes were found in the postvoid residual urine volume or maximal urinary flow rate in any group, and the acute urinary retention rates were low.

CONCLUSIONS

The results of our study have shown that tolterodine ER was efficacious in men with lower urinary tract symptoms, including overactive bladder, who had lower PSA levels (<1.3 ng/mL).

Authors+Show Affiliations

Department of Urology, University of Texas Southwestern, Medical Center at Dallas, Texas 75390-9110, USA. claus.roehrborn@utsouthwestern.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18817961

Citation

Roehrborn, Claus G., et al. "Effects of Serum PSA On Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB." Urology, vol. 72, no. 5, 2008, pp. 1061-7; discussion 1067.
Roehrborn CG, Kaplan SA, Kraus SR, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008;72(5):1061-7; discussion 1067.
Roehrborn, C. G., Kaplan, S. A., Kraus, S. R., Wang, J. T., Bavendam, T., & Guan, Z. (2008). Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology, 72(5), 1061-7; discussion 1067. https://doi.org/10.1016/j.urology.2008.06.067
Roehrborn CG, et al. Effects of Serum PSA On Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB. Urology. 2008;72(5):1061-7; discussion 1067. PubMed PMID: 18817961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. AU - Roehrborn,Claus G, AU - Kaplan,Steven A, AU - Kraus,Stephen R, AU - Wang,Joseph T, AU - Bavendam,Tamara, AU - Guan,Zhonghong, Y1 - 2008/09/25/ PY - 2008/02/11/received PY - 2008/05/16/revised PY - 2008/06/10/accepted PY - 2008/9/27/pubmed PY - 2008/12/17/medline PY - 2008/9/27/entrez SP - 1061-7; discussion 1067 JF - Urology JO - Urology VL - 72 IS - 5 N2 - OBJECTIVES: To evaluate the efficacy of tolterodine extended release (ER), tamsulosin, and tolterodine ER plus tamsulosin in men with symptoms of overactive bladder and benign prostatic hyperplasia stratified by prostate-specific antigen (PSA) level. METHODS: We performed a post hoc analysis of data from men >or=40 years old with frequency and urgency (with or without urge urinary incontinence), postvoid residual urine volume <200 mL, maximal urinary flow rate >5 mL/s, International Prostate Symptom Score (IPSS) of >or=12, and quality-of-life score of >or=3. They had been randomized to placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER plus tamsulosin for 12 weeks. The men were stratified by the median baseline PSA level (>or=1.3 vs <1.3 ng/mL). Assessments included changes in bladder diary variables and IPSSs. The men rated the urgency level of each micturition, and the frequency-urgency sum was defined as the total of these ratings. RESULTS: The PSA level correlated significantly with prostate size. Men with a PSA level of >or=1.3 ng/mL receiving tolterodine ER plus tamsulosin showed significantly greater improvements in 24-hour frequency, daytime frequency, the frequency-urgency sum, total IPSS, and IPSS storage score compared with those receiving placebo. Tamsulosin significantly improved the IPSS voiding scores, but tolterodine ER was ineffective. In men with a PSA level <1.3 ng/mL, tolterodine ER alone and tolterodine ER plus tamsulosin significantly improved the 24-hour frequency, daytime frequency, frequency-urgency sum, and IPSS storage scores compared with those receiving placebo; tamsulosin alone was ineffective. No significant changes were found in the postvoid residual urine volume or maximal urinary flow rate in any group, and the acute urinary retention rates were low. CONCLUSIONS: The results of our study have shown that tolterodine ER was efficacious in men with lower urinary tract symptoms, including overactive bladder, who had lower PSA levels (<1.3 ng/mL). SN - 1527-9995 UR - https://www.unboundmedicine.com/medline/citation/18817961/Effects_of_serum_PSA_on_efficacy_of_tolterodine_extended_release_with_or_without_tamsulosin_in_men_with_LUTS_including_OAB_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(08)00877-7 DB - PRIME DP - Unbound Medicine ER -